Evaluation of Adverse Drug Reaction in Patients Warfarin Therapy

Overview

Journal J Adv Pharm Technol Res

Date 2022 Dec 26

PMID 36568047

Authors

Norisca Aliza Putriana

Taofik Rusdiana

Tina Rostinawati

Mohammad Rizki Akbar

Dika Pramita Destiani

Affiliations

Soon will be listed here.

Abstract

This research aimed to understand the adverse drug reaction (ADR) in heart disease outpatients who were administered warfarin at a hospital in Bandung city. The research was conducted using a cross-sectional design with an observational approach. Subsequently, data were collected from 74 patients who met the inclusion criteria. The causality assessment was made by the Naranjo Algorithm and the incidence of bleeding was classified based on the Bleedscore™. The result showed that the most common ADR were nausea, dizziness, stomach ache, ecchymosis, petechiae, bleeding in the mouth, melena, etc. Furthermore, the INR value was the most significant factor in the incidence of ADR. It was 6.445 using a value of = 0.001 or a confidence interval of 95%. The most common side effect of warfarin in cardiac outpatients was superficial bleeding, followed by internal bleeding (melena). The INR value is the most significant factor in measuring the incidence of ADR.

Citing Articles

Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy.

Putriana N, Latarissa I, Rusdiana T, Rostinawati T, Akbar M Drug Des Devel Ther. 2025; 19:671-681.

PMID: 39896937 PMC: 11787782. DOI: 10.2147/DDDT.S497738.

Quality of Life of Patients Receiving Warfarin Therapy at a Tertiary Care Centre in Indonesia Using DASS (Duke Anticoagulation Satisfaction Scale).

Putriana N, Destiani D, Putri A, Latarissa I Vasc Health Risk Manag. 2024; 20:403-413.

PMID: 39206433 PMC: 11352524. DOI: 10.2147/VHRM.S467656.

Why Pharmacovigilance of Non-steroidal Anti-inflammatory Drugs is Important in India?.

Dash S, Singh P, Bajwa N, Choudhury A, Bisht P, Sharma R Endocr Metab Immune Disord Drug Targets. 2023; 24(7):731-748.

PMID: 37855282 DOI: 10.2174/0118715303247469230926092404.

References

Shehab N, Lovegrove M, Geller A, Rose K, Weidle N, Budnitz D . US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. JAMA. 2016; 316(20):2115-2125. PMC: 6490178. DOI: 10.1001/jama.2016.16201. View

Masubuchi N, Makino C, Murayama N . Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem Res Toxicol. 2007; 20(3):455-64. DOI: 10.1021/tx060234h. View

Ozturk M, Ipekci A, Kiyak S, Akdeniz Y, Aydin Y, Ikizceli I . Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department. J Clin Med Res. 2019; 11(2):106-113. PMC: 6340679. DOI: 10.14740/jocmr3669. View

Routledge P, OMahony M, Woodhouse K . Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004; 57(2):121-6. PMC: 1884428. DOI: 10.1046/j.1365-2125.2003.01875.x. View

Epstein R, Moyer T, Aubert R, O Kane D, Xia F, Verbrugge R . Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010; 55(25):2804-12. DOI: 10.1016/j.jacc.2010.03.009. View

Budnitz D, Shehab N, Kegler S, Richards C . Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007; 147(11):755-65. DOI: 10.7326/0003-4819-147-11-200712040-00006. View

Zhang M, Holman C, Price S, Sanfilippo F, Preen D, Bulsara M . Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009; 338:a2752. PMC: 2615549. DOI: 10.1136/bmj.a2752. View

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G . Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):160S-198S. DOI: 10.1378/chest.08-0670. View

Arulmani R, Rajendran S, Suresh B . Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol. 2007; 65(2):210-6. PMC: 2291214. DOI: 10.1111/j.1365-2125.2007.02993.x. View

10.

Reitsma P, van der Heijden J, Groot A, Rosendaal F, Buller H . A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005; 2(10):e312. PMC: 1251635. DOI: 10.1371/journal.pmed.0020312. View

11.

Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M . VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006; 80(2):169-78. DOI: 10.1016/j.clpt.2006.04.010. View

12.

Uygungul E, Ayrik C, Narci H, Erdogan S, Toker I, Demir F . Determining risk factors of bleeding in patients on warfarin treatment. Adv Hematol. 2014; 2014:369084. PMC: 4241733. DOI: 10.1155/2014/369084. View

13.

Bassi P, Osakwe A, Ogar C, Elagbaje C, Nwankwo B, Balogun S . Impact of comorbidity on adverse drug reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria. Pharmacol Res Perspect. 2017; 5(2):e00302. PMC: 5368966. DOI: 10.1002/prp2.302. View

14.

Fang M, Go A, Hylek E, Chang Y, Henault L, Jensvold N . Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006; 54(8):1231-6. PMC: 3534958. DOI: 10.1111/j.1532-5415.2006.00828.x. View

15.

Wadelius M, Chen L, Downes K, Ghori J, Hunt S, Eriksson N . Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005; 5(4):262-70. DOI: 10.1038/sj.tpj.6500313. View

16.

Gulseth M, Grice G, Dager W . Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm. 2009; 66(2):123-33. DOI: 10.2146/ajhp080127. View

17.

Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T . Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15-9. PMC: 443443. DOI: 10.1136/bmj.329.7456.15. View

18.

Gurwitz J, Field T, Harrold L, Rothschild J, DeBellis K, Seger A . Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003; 289(9):1107-16. DOI: 10.1001/jama.289.9.1107. View